A phase IV, 2x2 factorial, double blind study of 48 versus 96 weeks of PEGASYS 180 microg, with or without 24 weeks of entecavir in adult patients with HBeAg negative chronic hepatitis B.

Trial Profile

A phase IV, 2x2 factorial, double blind study of 48 versus 96 weeks of PEGASYS 180 microg, with or without 24 weeks of entecavir in adult patients with HBeAg negative chronic hepatitis B.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 25 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by Roche.
    • 23 Aug 2010 New trial record
    • 13 Aug 2010 Actual end date (Nov 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top